MX388893B - Formulaciones de anticuerpos estables acuosas. - Google Patents
Formulaciones de anticuerpos estables acuosas.Info
- Publication number
- MX388893B MX388893B MX2016004605A MX2016004605A MX388893B MX 388893 B MX388893 B MX 388893B MX 2016004605 A MX2016004605 A MX 2016004605A MX 2016004605 A MX2016004605 A MX 2016004605A MX 388893 B MX388893 B MX 388893B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody formulations
- stable antibody
- aqueous stable
- aqueous
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895143P | 2013-10-24 | 2013-10-24 | |
| PCT/US2014/061997 WO2015061584A1 (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004605A MX2016004605A (es) | 2016-11-14 |
| MX388893B true MX388893B (es) | 2025-03-20 |
Family
ID=52993565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004605A MX388893B (es) | 2013-10-24 | 2014-10-23 | Formulaciones de anticuerpos estables acuosas. |
| MX2021015825A MX2021015825A (es) | 2013-10-24 | 2016-04-11 | Formulaciones de anticuerpos estables acuosas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015825A MX2021015825A (es) | 2013-10-24 | 2016-04-11 | Formulaciones de anticuerpos estables acuosas. |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20150118249A1 (enExample) |
| EP (2) | EP3892288A1 (enExample) |
| JP (3) | JP6483673B2 (enExample) |
| KR (3) | KR20210041101A (enExample) |
| CN (4) | CN105611938B (enExample) |
| AU (4) | AU2014339984B2 (enExample) |
| BR (1) | BR112016008576B1 (enExample) |
| CA (1) | CA2926089C (enExample) |
| CY (1) | CY1125697T1 (enExample) |
| DK (1) | DK3060229T3 (enExample) |
| ES (1) | ES2893861T3 (enExample) |
| HR (1) | HRP20211371T1 (enExample) |
| HU (1) | HUE055919T2 (enExample) |
| LT (1) | LT3060229T (enExample) |
| MX (2) | MX388893B (enExample) |
| PL (1) | PL3060229T3 (enExample) |
| PT (1) | PT3060229T (enExample) |
| RS (1) | RS62419B1 (enExample) |
| RU (2) | RU2763787C2 (enExample) |
| SG (2) | SG10201803178UA (enExample) |
| SI (1) | SI3060229T1 (enExample) |
| SM (1) | SMT202100580T1 (enExample) |
| WO (1) | WO2015061584A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| AU2013256229A1 (en) * | 2012-05-03 | 2014-10-30 | Medimmune, Llc | Method for analyzing sample components |
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| EP3892288A1 (en) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Stable, aqueous antibody formulations |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| ES2744526T3 (es) | 2014-03-12 | 2020-02-25 | Prothena Biosciences Ltd | Anticuerpos anti-MCAM y métodos de uso asociados |
| WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| EP4606820A3 (en) * | 2015-11-30 | 2025-10-29 | Medimmune, LLC | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| ES2968923T3 (es) | 2016-08-10 | 2024-05-14 | Celltrion Inc | Preparación farmacéutica líquida estable de anticuerpo contra el virus de la gripe |
| AU2017345490B2 (en) | 2016-10-21 | 2022-07-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| CN113507938B (zh) * | 2019-03-29 | 2024-04-16 | 广东恒瑞医药有限公司 | 包含抗il-5抗体的药物组合物及其用途 |
| TW202126688A (zh) | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| JP7718272B2 (ja) * | 2019-12-16 | 2025-08-05 | ニプロ株式会社 | 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス |
| CN111024963A (zh) * | 2019-12-27 | 2020-04-17 | 桂林英美特生物技术研究所 | 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂 |
| KR20220152540A (ko) * | 2020-03-13 | 2022-11-16 | 삼성바이오에피스 주식회사 | 안정성이 증진된 액상 약제학적 조성물 |
| CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业（上海）股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
| CA3204307A1 (en) * | 2020-12-17 | 2022-06-23 | Astrazeneca Ab | Anti-il5r antibody formulations |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6018032A (en) * | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| JP2006502116A (ja) * | 2002-07-12 | 2006-01-19 | メダレックス， インク． | タンパク質の酸化分解を防ぐ方法及び組成物 |
| CN100448495C (zh) * | 2003-05-26 | 2009-01-07 | 白又寅 | 一次性注射器 |
| DE202006001995U1 (de) * | 2006-02-07 | 2006-06-08 | Sarstedt Ag & Co. | Probengefäß zur Aufnahme von kleinen Flüssigkeitsmengen für Analysen |
| GEP20125628B (en) * | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| DK3072525T3 (en) | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
| SG2014011365A (en) * | 2008-09-19 | 2014-05-29 | Hoffmann La Roche | Novel antibody formulation |
| CA2754528A1 (en) * | 2009-03-06 | 2010-09-10 | Genetech, Inc. | Antibody formulation |
| NZ613809A (en) * | 2009-05-04 | 2015-02-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| BR112014009031A2 (pt) * | 2011-10-18 | 2017-05-09 | Coherus Biosciences Inc | formulações de etanercept estabilizadas com íons de metais |
| EP2771358A4 (en) * | 2011-10-26 | 2015-08-26 | Bio Rad Laboratories | ELIMINATION OF VIRAL AGENTS IN MIXED MODE CHROMATOGRAPHY |
| CA2951856A1 (en) * | 2011-10-28 | 2013-05-02 | Integritybio Inc. | Protein formulations containing amino acids |
| US20140328839A1 (en) * | 2011-11-01 | 2014-11-06 | Medlmmune, Llc | Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma |
| KR102337599B1 (ko) * | 2013-08-12 | 2021-12-10 | 아스트라제네카 아베 | 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법 |
| WO2015023504A1 (en) * | 2013-08-12 | 2015-02-19 | Medlmmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| EP3892288A1 (en) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Stable, aqueous antibody formulations |
-
2014
- 2014-10-23 EP EP20207556.0A patent/EP3892288A1/en active Pending
- 2014-10-23 CN CN201480055263.0A patent/CN105611938B/zh active Active
- 2014-10-23 EP EP14855343.1A patent/EP3060229B1/en active Active
- 2014-10-23 KR KR1020217009731A patent/KR20210041101A/ko not_active Ceased
- 2014-10-23 DK DK14855343.1T patent/DK3060229T3/da active
- 2014-10-23 KR KR1020207012828A patent/KR102238065B1/ko active Active
- 2014-10-23 PL PL14855343T patent/PL3060229T3/pl unknown
- 2014-10-23 CN CN202110799711.XA patent/CN113350278B/zh active Active
- 2014-10-23 AU AU2014339984A patent/AU2014339984B2/en active Active
- 2014-10-23 WO PCT/US2014/061997 patent/WO2015061584A1/en not_active Ceased
- 2014-10-23 RS RS20211238A patent/RS62419B1/sr unknown
- 2014-10-23 RU RU2016119755A patent/RU2763787C2/ru active
- 2014-10-23 CA CA2926089A patent/CA2926089C/en active Active
- 2014-10-23 ES ES14855343T patent/ES2893861T3/es active Active
- 2014-10-23 CN CN202411964617.5A patent/CN119971024A/zh active Pending
- 2014-10-23 US US14/521,870 patent/US20150118249A1/en not_active Abandoned
- 2014-10-23 PT PT14855343T patent/PT3060229T/pt unknown
- 2014-10-23 SI SI201431876T patent/SI3060229T1/sl unknown
- 2014-10-23 MX MX2016004605A patent/MX388893B/es unknown
- 2014-10-23 SG SG10201803178UA patent/SG10201803178UA/en unknown
- 2014-10-23 LT LTEPPCT/US2014/061997T patent/LT3060229T/lt unknown
- 2014-10-23 SM SM20210580T patent/SMT202100580T1/it unknown
- 2014-10-23 KR KR1020167012565A patent/KR102109053B1/ko active Active
- 2014-10-23 JP JP2016525876A patent/JP6483673B2/ja active Active
- 2014-10-23 HR HRP20211371TT patent/HRP20211371T1/hr unknown
- 2014-10-23 RU RU2021137159A patent/RU2021137159A/ru unknown
- 2014-10-23 BR BR112016008576-0A patent/BR112016008576B1/pt active IP Right Grant
- 2014-10-23 HU HUE14855343A patent/HUE055919T2/hu unknown
- 2014-10-23 CN CN202010809794.1A patent/CN112107538A/zh active Pending
- 2014-10-23 SG SG11201603206UA patent/SG11201603206UA/en unknown
-
2016
- 2016-04-11 MX MX2021015825A patent/MX2021015825A/es unknown
-
2019
- 2019-02-14 JP JP2019024364A patent/JP6896781B2/ja active Active
- 2019-03-11 US US16/298,474 patent/US20190201535A1/en active Pending
-
2020
- 2020-03-25 US US16/829,659 patent/US20200297855A1/en not_active Abandoned
- 2020-07-09 AU AU2020204608A patent/AU2020204608A1/en not_active Abandoned
-
2021
- 2021-06-09 JP JP2021096239A patent/JP2021152034A/ja active Pending
- 2021-10-19 CY CY20211100902T patent/CY1125697T1/el unknown
-
2022
- 2022-12-23 AU AU2022291595A patent/AU2022291595B2/en active Active
-
2025
- 2025-02-04 US US19/045,166 patent/US20250170245A1/en active Pending
- 2025-09-12 AU AU2025230794A patent/AU2025230794A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388893B (es) | Formulaciones de anticuerpos estables acuosas. | |
| PH12019501931A1 (en) | Anti-pdl1 antibody formulations | |
| MA43187A (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| WO2014197849A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
| MA47664A1 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
| EA201691214A1 (ru) | Антитела к cd33 и иммуноконъюгаты | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| EA201591524A1 (ru) | Производные 2-аминопиримидина для лечения вирусных инфекций | |
| MD20150100A2 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
| EA201690618A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EA201590174A1 (ru) | Иммуноконъюгаты, содержащие анти-cd22 антитела | |
| EA201690280A1 (ru) | Композиции и способы, относящиеся к выделенным эндофитам | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112015009924A2 (pt) | formulações de proteína imunoglobulina de domínio variável duplo estáveis | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| UA115373C2 (uk) | Стабільний рідкий склад amg 416 (велкалсетиду) | |
| MA44550B1 (fr) | Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés | |
| EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
| EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
| EA201591725A1 (ru) | Твердые липидные наночастицы (ii) | |
| EA201492280A1 (ru) | Стабильный состав пексиганана | |
| EA201500927A1 (ru) | Твердые липидные наночастицы (i) |